
6. References

1. Medzhitov R. Origin and physiological roles of inflammation. *Nature*. **2008**, 454 (7203), 428-35.
2. Ferrero L, Nielsen H, Andersen S, Girardin E. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. *Clin Exp Immunol*. **2007**, 147 (2), 227-235.
3. Frank MM. Complement system, in Frank MM AK, Claman HN, Unanue ER, (eds): Samter's Immunologic Diseases. *Boston, Little, Brown and Company*. **1995**, 331-362.
4. Punchard NA, Whelan CJ, Adcock I. The Journal of Inflammation. *J Inflamm*. **2004**, 1 (1), 1-4.
5. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. **2017**, 9 (6), 7204-7218.
6. Lu L, Sun R, Liu M, Zheng Y, Zhang P. The Inflammatory Heart Diseases: Causes, Symptoms, and Treatments. *Cell Biochem Biophys*. **2015**, 72(3), 851-855.
7. Zindler E, Zipp F. Neuronal injury in chronic CNS inflammation. *Best Pract Res Clin Anaesthesiol*. **2010**, 24 (4), 551-562.
8. Barnum CJ, Tansey MG. Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease? *Curr Neurol Neurosci Rep*. **2012**, 12 (4), 350-358.
9. Smith A, Germolec R. Introduction to immunology and autoimmunity. *Environ Health Perspect*. **1999**, 107 (5), 661-665.
10. Cooper S, Stroehla C. The epidemiology of autoimmune diseases. *Autoimmun Rev*. **2003**, 2 (3), 119-125.

-
-
11. Bias WB, Reveille JD, Beaty TH, Meyers DA, Arnett FC. Evidence that autoimmunity in man is a Mendelian dominant trait. *Am J Hum Genet.* **1986**, 39 (5), 584-602.
 12. Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. *J Clin Med.* **2019**, 8 (7), 938.
 13. Yelin E. Work disability in rheumatic diseases. *Curr Opin Rheumatol.* **2007**, 19 (2), 91-96.
 14. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* **2021**, 71 (3), 209-249.
 15. Cancer: Facts, *Stats and Trends in India*, **2020**.
 16. Benjamin O, Bansal P, Goyal A, Lappin SL. Disease Modifying Anti-Rheumatic Drugs (DMARD). **2021**, In: StatPearls [Internet]. *Treasure Island (FL): StatPearls Publishing*; 2021 Jan.
 17. Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid Arthritis: A Brief Overview of the Treatment. *Med Princ Pract.* **2018**, 27 (6), 501-507.
 18. Mehmood RK. Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. *Oncol Rev.* **2014**, 8(2), 256.
 19. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillermin G, Chateaux C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and

-
-
- prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. *Lancet*. **2007**, 370 (9594), 1209-1218.
20. Robati M, Holtz D, Dunton CJ. A review of topotecan in combination chemotherapy for advanced cervical cancer. *Ther Clin Risk Manag*. **2008**, 4 (1), 213-218.
21. Gao Y, Shang Q, Li W, Guo W, Stojadinovic A, Mannion C, Man YG, Chen T. Antibiotics for cancer treatment: A double-edged sword. *J Cancer*. **2020**, 11 (17), 5135-5149.
22. Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. *Front Mol Biosci*. **2014**, 1, 24.
23. Chu DT, Nguyen TT, Tien NLB, Tran DK, Jeong JH, Anh PG, Thanh VV, Truong DT, Dinh TC. Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications. *Cells*. **2020**, 9 (3), 563.
24. Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. *Adv Ther*. **2017**, 34 (10), 2232-2273.
25. Richardson PG, Beksaç M, Špička I, Mikhael J. Isatuximab for the treatment of relapsed/refractory multiple myeloma. *Expert Opin Biol Ther*. **2020**, 20 (12), 1395-1404.
26. Cai WQ, Zeng LS, Wang LF, Wang YY, Cheng JT, Zhang Y, Han ZW, Zhou Y, Huang SL, Wang XW, Peng XC, Xiang Y, Ma Z, Cui SZ, Xin HW. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. *Front Oncol*. **2020**, 10, 1249.
27. Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. *N Engl J Med*. **2002**, 346 (9), 683-693.
-
-

-
-
28. Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwarb H, Le Cesne A, Koeberle D, Bärtschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). *Cancer*. **2018**, 124 (7), 1449-1454.
29. Motzer RJ, Escudier B, Gannon A, Figlin RA. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. *Oncologist*. **2017**, 22 (1), 41-52.
30. Paul B, Trovato JA, Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. *Am J Health Syst Pharm*. **2008**, 65 (18), 1703-1710.
31. Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. *Signal Transduct Target Ther*. **2021**, 31, 6 (1), 201.
32. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. *Science*. **2002**, 298 (5600), 1912-1934.
33. Roy S, Vega M, Harmer J. Carbohydrate Kinases: A Conserved Mechanism Across Differing Folds, *Catalysts*. **2019**, 9 (29), 1-19.
34. Sun Y, Thapa N, Hedman AC, Anderson RA. Phosphatidylinositol 4,5-bisphosphate: targeted production and signaling. *Bioessays*. **2013**, 35 (6), 513-522.
-
-

-
-
35. Heath CM, Stahl PD, Barbieri MA. Lipid kinases play crucial and multiple roles in membrane trafficking and signaling. *Histol Histopathol.* **2003**, 18 (3), 989-998.
36. Gao Y, Gao F, Chen K, Tian ML, Zhao DL. Sphingosine kinase 1 as an anticancer therapeutic target. *Drug Des Devel Ther.* **2015**, 9, 3239-3245.
37. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. *Biochim Biophys Acta.* **1998**, 1436 (1-2), 127-150.
38. a) Kivens WJ, Hunt SW 3rd, Mobley JL, Zell T, Dell CL, Bierer BE, Shimizu Y. Identification of a proline-rich sequence in the CD2 cytoplasmic domain critical for regulation of integrin-mediated adhesion and activation of phosphoinositide 3-kinase. *Mol Cell Biol.* **1998**, 18(9), 5291-5307.
- b) Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat Rev Genet.* **2006**, 7(8), 606-619.
39. Backer JM. The regulation and function of Class III PI3Ks: novel roles for Vps34. *Biochem J.* **2008**, 410(1), 1-17.
40. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. *Exp Cell Res.* **1999**, 253(1), 239-254.
41. Guo H, German P, Bai S, Barnes S, Guo W, Qi X, Lou H, Liang J, Jonasch E, Mills GB, Ding Z. The PI3K/AKT Pathway and Renal Cell Carcinoma. *J Genet Genomics.* **2015**, 42(7), 343-353.
42. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. *Cell.* **2007**, 129(7), 1261-1274.
43. Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? *Nat Rev Immunol.* **2007**, 7(3), 191-201.
-
-

-
-
44. Somoza JR, Koditek D, Villaseñor AG, Novikov N, Wong MH, Liclican A, Xing W, Lagpacan L, Wang R, Schultz BE, Papalia GA, Samuel D, Lad L, McGrath ME. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ . *J Biol Chem.* **2015**, 290(13), 8439-8446.
45. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med.* **2014**, 370(11), 1008-1018.
46. Hoegenauer K, Soldermann N, Zécri F, Strang RS, Graveleau N, Wolf RM, Cooke NG, Smith AB, Hollingworth GJ, Blanz J, Gutmann S, Rummel G, Littlewood-Evans A, Burkhart C. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. *ACS Med Chem Lett.* **2017**, 8(9), 975-980.
47. Lampson BL, Brown JR. PI3K δ -selective and PI3K α/δ -combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. *Expert Opin Investig Drugs.* **2017**, 26(11), 1267-1279.
48. Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson AJ. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. *Blood.* **2014**, 124(24), 3583-3586.
49. Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, Scott WJ, Mumberg D, Ziegelbauer K. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 α and p110 δ activities in tumor cell lines and xenograft models. *Mol Cancer Ther.* **2013**, 12(11), 2319-2330.
-
-

-
-
50. Calero R, Morchon E, Martinez-Argudo I, Serrano R. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. *Cancer Lett.* **2017**, 406, 1-11.
51. Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS. Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. *Clin Cancer Res.* **2016**, 22(12), 2874-2884.
52. Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. *Clin Cancer Res.* **2013**, 19(14), 3808-3819.
53. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. *Mol Cancer Ther.* **2012**, 11(2), 317-328.
54. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, Knighton DR, Li J, Liu KK, Liu Z, Marx MA, Walls M, Wells PA, Yin MJ, Zhu J, Zientek M. Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. *ACS Med Chem Lett.* **2012**, 4(1), 91-97.
-
-

-
-
55. Berndt A, Miller S, Williams O, Le DD, Houseman BT, Pacold JI, Gorrec F, Hon WC, Liu Y, Rommel C, Gaillard P, Rückle T, Schwarz MK, Shokat KM, Shaw JP, Williams RL. The p110 delta structure: mechanisms for selectivity and potency of new PI (3) K inhibitors. *Nat Chem Biol.* **2010**, 6(2), 117-124.
56. Miller MS, Thompson PE, Gabelli SB. Structural Determinants of Isoform Selectivity in PI3K Inhibitors. *Biomolecules.* **2019**, 9(3), 82.
57. Ren A, Liu Y, Li L, Chan K, Wilson T, Heterocyclic kinase inhibitors, *WO2010036380*.
58. Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, Luengo JI, Newlander KA, Parrish CA, Ridgers LH, Sarpong MA, Schmidt SJ, Van Aller GS, Carson JD, Diamond MA, Elkins PA, Gardiner CM, Garver E, Gilbert SA, Gontarek RR, Jackson JR, Kershner KL, Luo L, Raha K, Sherk CS, Sung CM, Sutton D, Tummino PJ, Wegrzyn RJ, Auger KR, Dhanak D. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. *ACS Med Chem Lett.* **2010**, 1(1), 39-43.
59. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW, Knighton DR, Li J, Liu KK, Liu Z, Marx MA, Walls M, Wells PA, Yin MJ, Zhu J, Zientek M. Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. *ACS Med Chem Lett.* **2012**, 4(1), 91-97.
60. Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. *Mol Cancer.* **2017**, 16(1), 100.
-
-

-
-
61. Hei YY, Xin M, Zhang H, Xie XX, Mao S, Zhang SQ. Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors. *Bioorg Med Chem Lett.* **2016**, 26(18), 4408-4413.
62. Bahekar R, Dave B, Soman S, Patel D, Chopade R, Funde R, Kumar J, Sachchidanand S, Giri P, Chatterjee A, Mahapatra J, Vyas P, Ghoshdastidar K, Bandyopadhyay D, Desai RC. Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3K δ selective inhibitors. *Bioorg Med Chem Lett.* **2019**, 29(11), 1313-1319.
63. Ladani G, Patel M. Synthesis of imidazo [4, 5-c] quinoline derivatives via hofmann rearrangement in the presence of iodobenzene diacetate and its biological evaluation. *Heterocyclic Letters*, **2016**, 6(3), 459-469.
64. Patel PR, Sun W, Kim M, Huang X, Sanderson PE, Tanaka TQ, McKew JC, Simeonov A, Williamson KC, Zheng W, Huang W. In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents. *Bioorg Med Chem Lett.* **2016**, 26(12), 2907-2911.
65. Spencer CF, Synder HR Jr, Burch HA, Hatton CJ. Imidazo [4, 5-f]quinolines. 2. A series of 9-(substituted amino) imidazo [4, 5-f]quinolines as antitapeworm agents. *J Med Chem.* **1977**, 20(6), 829-833.
66. Thigulla Y, Akula M, Trivedi P, Ghosh B, Jha M, Bhattacharya A. Synthesis and anti-cancer activity of 1,4-disubstituted imidazo[4,5-c]quinolines. *Org Biomol Chem.* **2016**, 14(3), 876-883.
67. N. Senthilkumar and Y. D. Ravichandran, *J. Indian Chem. Soc.* **2015**, 92, 921.
68. Venkatesan A, Agarwal A, Abe T, Ushirogochi H, Takasaki T, Mihira A, Mansour TS. Targeting Val 216 in class A beta-lactamases with tricyclic 6-methylidene penems. *ChemMedChem.* **2008**, 3(11), 1658-1661.
-
-

-
-
69. Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Furuta Y, Sakai M, Horiguchi M, Masui Y, Okazaki K, Sato Y, Nakahira H. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. *Bioorg Med Chem.* **2012**, 20(19), 5864-5883.
70. Seixas JD, Luengo-Arratta SA, Diaz R, Saldivia M, Rojas-Barros DI, Manzano P, Gonzalez S, Berlanga M, Smith TK, Navarro M, Pollastri MP. Establishment of a structure-activity relationship of 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness. *J Med Chem.* **2014**, 57(11), 4834-4848.
71. Stowasser F, Banziger M, Garad S D. Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, *WO 2008064093*.
72. Stamatkin C, Ratermann KL, Overley CW, Black EP. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. *Cancer Biol Ther.* **2015**, 16(9), 1341-1352.
73. Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, Keng Magdalene KH, Tan SH, Lange M, Tan SY, Mumberg D, Lim ST, Ziegelbauer K, Liu N. Simultaneous Inhibition of PI3K δ and PI3K α Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF- κ B and AKT. *Cancer Cell.* **2017**, 31(1), 64-78.
74. Bevaart L, Vervoordeldonk MJ, Tak PP. Collagen-induced arthritis in mice. *Methods Mol Biol.* **2010**, 602, 181-192.
75. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, Martin CM, Hoyt JG, Tillotson B, Murphy EL, Lim AR, Thomas BD, Macdougall JR, Ren P, Liu Y, Li LS, Jessen KA, Fritz CC, Dunbar JL, Porter JR, Rommel C, Palombella VJ, Changelian PS, Kutok JL.
-
-

-
-
- PI3K- δ and PI3K- γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. *Chem Biol.* **2013**, 20(11), 1364-1374.
76. Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development. *Med Res Rev.* **2001**, 21(5), 397-411.
77. Chaudhary KW, O'Neal JM, Mo ZL, Fermini B, Gallavan RH, Bahinski A. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade. *Assay Drug Dev Technol.* **2006**, 4(1), 73-82.
78. Schrödinger Release 2018-3: Glide, Schrödinger, LLC, New York, NY, **2018**.
79. EMA/CHMP/324336/**2014**
80. Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. *J Med Chem.* **2011**, 54(8), 2529-2591
81. Buckley G, Cooper N, Dyke HJ, Galleway F, Gowers L, Gregory JC, Hannah DR, Haughan AF, Hellewell PG, Kendall HJ, Lowe C, Maxey R, Montana JG, Naylor R, Picken CL, Runcie KA, Sabin V, Tuladhar BR, Warneck JB. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma. *Bioorg Med Chem Lett.* **2000**, 10(18), 2137-2140.
82. Buckley GM, Cooper N, Dyke HJ, Galleway FP, Gowers L, Haughan AF, Kendall HJ, Lowe C, Maxey R, Montana JG, Naylor R, Oxford J, Peake JC, Picken CL, Runcie KA, Sabin V, Sharpe A, Warneck JB. 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma. *Bioorg Med Chem Lett.* **2002**, 12(12), 1613-1615.
83. Fang C, Lee KK, Nietupski R, Bates RH, Fernandez-Menendez R, Lopez-Roman EM, Guijarro-Lopez L, Yin Y, Peng Z, Gomez JE, Fisher S, Barros-Aguirre D, Hubbard BK, Serrano-Wu MH, Hung DT. Discovery of
-
-

-
- heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. *Bioorg Med Chem Lett.* **2018**, 28(22), 3529-3533.
84. Ebiike H, Masubuchi M, Liu P, Kawasaki K, Morikami K, Sogabe S, Hayase M, Fujii T, Sakata K, Shindoh H, Shiratori Y, Aoki Y, Ohtsuka T, Shimma N. Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2. *Bioorg Med Chem Lett.* **2002**, 12(4), 607-610.
85. P. Yadav, P. Singh, A. K. Tewari, Design, synthesis, docking and anti-inflammatory evaluation of novel series of benzofuran based prodrugs, *Bioorg. Med. Chem. Lett.* **2014**, 24, 2251–2255.
86. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. *Cancer Cell.* **2003**, 4(6), 463-476.
87. Salomé C, Narbonne V, Ribeiro N, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L. Benzofuran derivatives as a novel class of inhibitors of mTOR signaling. *Eur J Med Chem.* **2014**, 74, 41-49.
88. hi W, Lowary TL. Reprint of "effect of carbohydrate amino group modifications on the cytotoxicity of glycosylated 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans". *Bioorg Med Chem Lett.* **2011**, 21, 2591-2596.
89. Latif N.A, Hafez H, Break M. Synthesis of new benzofuran-1,3-thiazolidin-4-one derivatives from natural sources and study of their antioxidant activity. *Russ J Bioorg Chem.* **2013**, 39, 438–443.
90. Javali C, Karvekar M. Synthesis of N'-(Substituted benzylidene)-1-benzofuran-2-carbohydrazide and 5-(5-Substituted-1-benzofuran-2-yl) 1,3,4-
-

-
-
- oxadiazole-2-thiol as Potent Antioxidants. *Asian Journal of Chemistry*. **2008**, 20(6), 4531-4535.
91. Kishor RM. Review on Synthetic Routes for Synthesis of Benzofuran-Based Compounds. *J. Chemical and Pharmaceutical Research*, **2017**, 9(5), 210-220
92. Perkin W. On some new bromine derivatives of coumarin, *J. Chem Soc.* **1870**, 23, 368-371.
93. Sapkal S, Shelke K, Shingate B, Shingare M. An efficient synthesis of benzofuran derivatives under conventional/non-conventional method, *Chinese Chemical Letters*. **2010**, 21(12), 1439-1442,
94. McMurry J. Carbonyl-coupling reactions using low-valent titanium. *Chem. Rev.* **1989**, 89, 1513-1524.
95. Eldehna WM, Nocentini A, Elsayed ZM, Al-Warhi T, Aljaeed N, Alotaibi OJ, Al-Sanea MM, Abdel-Aziz HA, Supuran CT. Benzofuran-Based Carboxylic Acids as Carbonic Anhydrase Inhibitors and Antiproliferative Agents against Breast Cancer. *ACS Med Chem Lett.* **2020**, 11(5), 1022-1027.
96. Yamabe H, Okuyama M, Nakao A, Ooizumi M, Saito K. Preparation of cyclic amide derivatives as sigma receptor ligands. *WO2001064670*.
97. Ouvry G, Clary L, Tomas L, Aurelly M, Bonnary L, Borde E, Bouix-Peter C, Chantalat L, Defoin-Platel C, Deret S, Forissier M, Harris CS, Isabet T, Lamy L, Luzy AP, Pascau J, Soulet C, Taddei A, Taquet N, Thoreau E, Varvier E, Vial E, Hennequin LF. Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors. *ACS Med Chem Lett.* **2019**, 10(11), 1561-1567.
98. Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. *Redox Biol.* **2015**, 6, 318-325.
-
-

-
-
99. Das J, Rao CV, Sastry TV, Roshaiiah M, Sankar PG, Khadeer A, Kumar MS, Mallik A, Selvakumar N, Iqbal J, Trehan S. Effects of positional and geometrical isomerism on the biological activity of some novel oxazolidinones. *Bioorg Med Chem Lett.* **2005**, 15(2), 337-343.
100. Kumar S, Bawa S, Gupta H. Biological activities of quinoline derivatives. *Mini Rev Med Chem.* **2009**, 9(14), 1648-1654.
101. Musiol R, Serda M, Hensel-Bielowka S, Polanski J. Quinoline-based antifungals. *Curr Med Chem.* **2010**, 17(18), 1960-1973.
102. Kaur K, Jain M, Reddy RP, Jain R. Quinolines and structurally related heterocycles as antimalarials. *Eur J Med Chem.* **2010**, 45(8), 3245-3264.
103. Solomon VR, Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. *Eur J Pharmacol.* **2009**, 625(1-3), 220-233.
104. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discifani C, Davis R, Shi X, Rabindran SK, Gruber BC, Ye F, Hallett WA, Nilakantan R, Shen R, Wang YF, Greenberger LM, Tsou HR. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). *J Med Chem.* **2003**, 46(1), 49-63.
105. Wissner A, Berger DM, Boschelli DH, Floyd MB Jr, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Shen R, Tsou HR, Upešlaciš E, Wang YF, Wu B, Ye F, Zhang N. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. *J Med Chem.* **2000**, 43(17), 3244-3256.
-
-

-
106. Wissner A, Brawner Floyd MB, Rabindran SK, Nilakantan R, Greenberger LM, Shen R, Wang YF, Tsou HR. Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. *Bioorg Med Chem Lett.* **2002**, 12(20), 2893-2897.
107. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, Rosfjord EC, Discafani C, Davis R, Shi X, Rabindran SK, Gruber BC, Ye F, Hallett WA, Nilakantan R, Shen R, Wang YF, Greenberger LM, Tsou HR. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). *J Med Chem.* **2003**, 46(1), 49-63.
108. Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak RS, Nilakantan R, Discafani C, Golas J, Rabindran SK, Shen R, Shi X, Wang YF, Upešlaciš J, Wissner A. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. *J Med Chem.* **2005**, 48(4), 1107-1131.
109. Zhang N, Wu B, Powell D, Wissner A, Floyd MB, Kovacs ED, Toral-Barza L, Kohler C. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. *Bioorg Med Chem Lett.* **2000**, 10(24), 2825-2828.
110. Zhang N, Wu B, Eudy N, Wang Y, Ye F, Powell D, Wissner A, Feldberg LR, Kim SC, Mallon R, Kovacs ED, Toral-Barza L, Kohler CA. MEK (MAPKK) inhibitors. Part 2: structure-activity relationships of 4-anilino-3-
-

-
- cyano-6,7-dialkoxyquinolines. *Bioorg Med Chem Lett.* **2001**, 11(11), 1407-1410.
111. Berger D, Dutia M, Powell D, Wu B, Wissner A, Boschelli DH, Floyd MB, Zhang N, Torres N, Levin J, Du X, Wojciechowicz D, Discafani C, Kohler C, Kim SC, Feldberg LR, Collins K, Mallon R. Synthesis and evaluation of 4-anilino-6,7-dialkoxy-3-quinolinecarbonitriles as inhibitors of kinases of the Ras-MAPK signaling cascade. *Bioorg Med Chem Lett.* **2003**, 13(18), 3031-3034.
112. Mallon R, Feldberg L, Kim S, Collins K, Wojciechowicz D, Kohler C, Kovacs D, Discafani C, Zhang N, Wu B, Floyd B, Powell D, Berger D. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. *Mol Cancer Ther.* **2004**, 3(6), 755-762.
113. Berger DM, Dutia M, Powell D, Floyd MB, Torres N, Mallon R, Wojciechowicz D, Kim S, Feldberg L, Collins K, Chaudhary I. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors. *Bioorg Med Chem.* **2008**, 16(20), 9202-9211.
114. Petra Černuchová, Giang Vo-Thanh, Viktor Milata, André Loupy, Soňa Jantová, Marica Theiszová, Utilization of 2-ethoxymethylene-3-oxobutanenitrile in the synthesis of heterocycles possessing biological activity, *Tetrahedron*, **2005**, 61(22), 5379-5387
115. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). *Bioorg Med Chem Lett.* **2003**, 13(24), 4355-4359.
-

-
-
116. Sawyer JS, Beight DW, Britt KS, Anderson BD, Campbell RM, Goodson T Jr, Herron DK, Li HY, McMillen WT, Mort N, Parsons S, Smith EC, Wagner JR, Yan L, Zhang F, Yingling JM. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. *Bioorg Med Chem Lett.* **2004**, 14(13), 3581-3584.
117. Li HY, Wang Y, Yan L, Campbell RM, Anderson BD, Wagner JR, Yingling JM. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines. *Bioorg Med Chem Lett.* **2004**, 14(13), 3585-3588.
118. Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS, Huss KL, Voss MD, Wang Y, Clawson DK, Yingling JM, Sawyer JS. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent. *J Med Chem.* **2008**, 51(7), 2302-2306.
119. Daniel KG, Gupta P, Harbach RH, Guida WC, Dou QP. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. *Biochem Pharmacol.* **2004**, 67(6), 1139-1151.
120. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. *Breast Cancer Res.* **2005**, 7(6), 897-908.
121. Adsule S, Barve V, Chen D, Ahmed F, Dou QP, Padhye S, Sarkar FH. Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as
-
-

-
- proteasome inhibitors in human prostate cancer cells. *J Med Chem.* **2006**, 49(24), 7242-7246.
122. Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, Miller K, Powell DW, Yaczko D, Young M, Tischler M, Arndt K, Discafani C, Etienne C, Gibbons J, Grod J, Lucas J, Weber JM, Boschelli F. Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. *J Med Chem.* **2001**, 44(23), 3965-3977.
123. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. *Cancer Res.* **2003**, 63(2), 375-381.
124. Boschelli DH, Wang YD, Johnson S, Wu B, Ye F, Barrios Sosa AC, Golas JM, Boschelli F. 7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. *J Med Chem.* **2004**, 47(7), 1599-1601.
125. Boschelli DH, Wu B, Ye F, Durutlic H, Golas JM, Lucas J, Boschelli F. Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs. *Bioorg Med Chem.* **2008**, 16(1), 405-412.
126. Berger D, Dutia M, Powell D, Wissner A, DeMorin F, Raifeld Y, Weber J, Boschelli F. Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. *Bioorg Med Chem Lett.* **2002**, 12(20), 2989-2992.
127. Tao, P., Li, W.-L., Zhang, J., Guo, S., Zhao, Q., Wang, H., Wei, B., Liu, S.-J., Zhou, X.-H., Yu, Q., Xu, B.-S. and Huang, W. Facile Synthesis of Highly Efficient Lepidine-Based Phosphorescent Iridium(III) Complexes for Yellow and White Organic Light-Emitting Diodes. *Adv. Funct. Mater.* **2016**, 26, 881-894.
-